Luis Roberto Tlapa Monge

Dr. Luis Roberto Tlapa Monge

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
LMLuis Roberto Tlapa Monge
Luis Roberto Tlapa Monge
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
Alzheimer’s disease (AD) is traditionally defined by Amyloid-β (Aβ) plaques and tau neurofibrillary tangles, yet these proteinopathies alone fail to explain disease heterogeneity, progression, and cognitive decline. Emerging evidence identifies chronic neuroinflammation as a central integrator that converts molecular pathology into synaptic failure and neurodegeneration. In this context, Aβ acts as a danger-associated molecular pattern that activates microglial and astrocytic immune programs through receptors such as TREM2, TLRs, and RAGE, leading to inflammasome activation, cytokine release, and oxidative stress. These responses pathologically re-engage developmental complement pathways (C1q–C3–CR3), driving excessive synaptic pruning that correlates more closely with cognitive impairment than neuronal loss. Reactive astrocytes further amplify dysfunction by impairing glutamate and potassium homeostasis, promoting excitotoxic and metabolic stress, while inflammatory glia facilitate prion-like tau propagation via extracellular vesicles. Concurrent neurovascular inflammation disrupts blood–brain barrier integrity and cerebral perfusion, reinforcing immune-metabolic failure. Importantly, neuroinflammatory biomarkers (GFAP, sTREM2, YKL-40, cytokines, complement, and TSPO-PET) provide dynamic readouts of disease activity and therapeutic response. Together, these findings position AD as a disorder of failed immune resolution and support precision immunomodulatory and pro-resolving therapies aimed at restoring neuroimmune homeostasis rather than merely removing protein aggregates.

6 January 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
LMLuis Roberto Tlapa Monge
Luis Roberto Tlapa Monge
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis, and Huntington’s disease represent a major challenge in neuroscience due to their complex, multifactorial nature and the absence of curative treatments. These disorders share common molecular mechanisms, including oxidative stress, mitochondrial dysfunction, proteostasis collapse, calcium dyshomeostasis, chronic neuroinflammation, and the prion-like propagation of misfolded proteins. Together, these processes trigger a cascade of cellular damage that culminates in synaptic dysfunction and programmed neuronal death. This review integrates current evidence on the sequential stages of neurodegeneration, emphasizing the convergence of oxidative, inflammatory, and proteotoxic pathways that drive neuronal vulnerability. Moreover, it explores emerging therapeutic strategies aimed at restoring cellular homeostasis, such as Nrf2 activation, modulation of the unfolded protein response (UPR), enhancement of autophagy, immunotherapy against pathological proteins, and gene therapy approaches. The dynamic interplay among mitochondria, endoplasmic reticulum, and glial cells is highlighted as a central element in disease progression. Understanding these interconnected mechanisms provides a foundation for developing multi-targeted interventions capable of halting or delaying neuronal loss and improving clinical outcomes in neurodegenerative disorders. This work provides an integrative and introductory overview of the convergent mechanisms underlying neurodegeneration rather than an exhaustive mechanistic analysis.

10 June 2026 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
LMLuis Roberto Tlapa Monge
Luis Roberto Tlapa Monge
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez

4 May 2026 in Future Virology
Verified
Journal Article
Closed access
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
LMLuis Roberto Tlapa Monge
Luis Roberto Tlapa Monge
SMSonia Lilia Mestizo-Gutiérrez
Sonia Lilia Mestizo-Gutiérrez
1. SARS-CoV-2, the causative agent of the COVID-19 pandemic, was first identified in December 2019 in the city of Wuhan, China [1,2]. This marked the beginning of a global health crisis unprecedent...